tricida, inc. is an innovative pre-clinical stage biopharmaceutical company, founded in 2013, and focused on the discovery and development of first-in-class therapeutics for metabolic, renal and cardiovascular disease. tricida’s lead program is trc101, a novel treatment for complications of chronic kidney disease (ckd). tricida is led by an experienced and accomplished management team that has worked together for 10 plus years and has raised >$250 m in venture capital from world-class investors over three companies. this team brings their proven leadership and expertise to address the specific disease profile of chronic kidney disease and related complications. the national health and nutrition examination surveys (nhanes, 1988-1994 and 1999-2004) estimate that over 26 million adults in the united states have chronic kidney disease, with substantial morbidity and mortality associated with the progressive loss of kidney function. the scientists and clinicians at tricida aim to provide p
Company profile
Ticker
TCDAQ
Exchange
Website
CEO
Gerrit Klaerner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
TCDAQ stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
20 Jun 23
15-12G
Securities registration termination
13 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jun 23
POSASR
Automatic shelf registration (post-effective amendment)
13 Jun 23
POS AM
Prospectus update (post-effective amendment)
13 Jun 23
8-K
Bankruptcy or Receivership
13 Jun 23
8-K
Bankruptcy or Receivership
25 May 23
8-K
Regulation FD Disclosure
26 Apr 23
8-K
Regulation FD Disclosure
24 Mar 23
8-K
Departure of Directors or Certain Officers
21 Mar 23
Transcripts
TCDAQ
Earnings call transcript
2022 Q2
9 Aug 22
TCDAQ
Earnings call transcript
2022 Q1
15 May 22
TCDAQ
Earnings call transcript
2021 Q4
29 Mar 22
TCDAQ
Earnings call transcript
2021 Q3
8 Nov 21
TCDAQ
Earnings call transcript
2021 Q2
10 Aug 21
TCDAQ
Earnings call transcript
2021 Q1
9 May 21
TCDAQ
Earnings call transcript
2020 Q4
28 Feb 21
TCDAQ
Earnings call transcript
2020 Q2
8 Aug 20
TCDAQ
Earnings call transcript
2020 Q1
10 May 20
TCDAQ
Earnings call transcript
2019 Q4
28 Feb 20
Latest ownership filings
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13G/A
Frazier Life Sciences Public Fund, L.P.
14 Feb 23
SC 13G/A
Deep Track Capital, LP
14 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13D/A
Sibling Capital Ventures LLC
16 Dec 22
4
Change in insider ownership
25 Nov 22
4
David P Bonita
25 Nov 22
SC 13D/A
ORBIMED ADVISORS LLC
25 Nov 22
4
Robert J Alpern
25 Nov 22
4
Robert J Alpern
22 Nov 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm |
Cash burn (monthly) | 1.47 mm | (no burn) | 8.02 mm | 10.36 mm | 6.25 mm | 9.07 mm |
Cash used (since last report) | 27.72 mm | n/a | 151.28 mm | 195.36 mm | 117.87 mm | 171.01 mm |
Cash remaining | -9.97 mm | n/a | -133.53 mm | -177.61 mm | -100.13 mm | -153.26 mm |
Runway (months of cash) | -6.8 | n/a | -16.7 | -17.1 | -16.0 | -16.9 |
Institutional ownership, Q1 2023
12.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 75 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 92.27 mm |
Total shares | 7.51 mm |
Total puts | 38.00 |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Longitude Capital Partners II | 3.02 mm | $90.62 mm |
Venrock Healthcare Capital Partners II | 2.98 mm | $1.65 mm |
Frazier Life Sciences Public Fund | 1.50 mm | $0.00 |
FNY Investment Advisers | 4.80 k | $0.00 |
BCS Barclays | 753.00 | $0.00 |
Tower Research Capital | 94.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Nov 22 | Bonita David P | Common Stock | Sell | Dispose S | Yes | No | 0.22 | 3,629,226 | 798.43 k | 0 |
25 Nov 22 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 0.22 | 3,629,226 | 798.43 k | 0 |
23 Nov 22 | Alpern Robert J | Common Stock | Sell | Dispose S | No | No | 0.21 | 131,879 | 27.69 k | 0 |
23 Nov 22 | Bonita David P | Common Stock | Sell | Dispose S | Yes | No | 0.21 | 5,617,300 | 1.18 mm | 3,629,226 |
23 Nov 22 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 0.21 | 5,617,300 | 1.18 mm | 3,629,226 |
22 Nov 22 | Bonita David P | Common Stock | Sell | Dispose S | Yes | No | 0.22 | 1,034,421 | 227.57 k | 9,246,526 |
22 Nov 22 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 0.22 | 1,034,421 | 227.57 k | 9,246,526 |
21 Nov 22 | Alpern Robert J | Common Stock | Sell | Dispose S | No | No | 0.23 | 27,584 | 6.34 k | 131,879 |